Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revatropate

Drug Profile

Revatropate

Alternative Names: UK 112166; UK 112166-04

Latest Information Update: 21 Mar 2000

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antiasthmatics; Bronchodilators; Quinuclidines; Small molecules
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 21 Mar 2000 No-Development-Reported for Chronic obstructive pulmonary disease in European Union (Inhalation)
  • 25 Sep 1997 New profile
  • 25 Sep 1997 Phase-II clinical trials for Chronic obstructive pulmonary disease in European Union (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top